CS-2759
CS-2759 性质
| 熔点 | 165 - 168°C |
|---|---|
| 储存条件 | -20°C Freezer, Under inert atmosphere |
| 溶解度 | 可溶于DMSO（少许）、甲醇（少许） |
| 形态 | 固体 |
| 颜色 | 白色至类白色 |
| InChI | InChI=1S/C19H23NO.ClH/c1-20(2)15-18-13-14-21-19(18,16-9-5-3-6-10-16)17-11-7-4-8-12-17;/h3-12,18H,13-15H2,1-2H3;1H |
| InChIKey | FEQOLYDPQKHFTD-UHFFFAOYSA-N |
| SMILES | C(C1CCOC1(C1C=CC=CC=1)C1C=CC=CC=1)N(C)C.Cl |
CS-2759 用途与合成方法
| Target | Value |
|
muscarinic
() | |
|
sigma-1 receptor
(Cell-free assay) | 0.86 μM |
The pre-administration of Blarcamesine (ANAVEX2-73) leads to a dose-dependent attenuation of the scopolamine induced alternation deficit, significant at 1 and 3 mg/kg. The pre-treatment with Blarcamesine hydrochloride attenuates the impairments of step-through latency, dose dependently and significantly at doses higher than 0.3 mg/kg. The Blarcamesine hydrochloride treatment dose-dependently blocks the recognition memory deficit, with a significant effect measured at 1 mg/kg. One day after injections, the significant Aβ 25-35 -induced decrease in Akt phosphorylation is significantly attenuated by Blarcamesine hydrochloride at 0.1 and 1 mg/kg dose. Seven days after injections, Blarcamesine hydrochloride attenuates the decrease in Ser 9 phosphorylation induced by the peptide at 0.3 and 1 mg/kg. The Blarcamesine hydrochloride treatment dose-dependently prevents the Aβ 25-35 -induced increase in Aβ 1-42 content, with a significant effect at the highest dose tested.
CS-2759 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-101864 | 195615-84-0 | 1 mg | 277 | |
| 2026-09-15 | HY-101864 | CS-2759 | 195615-84-0 | 5mg | 610 |
